These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

429 related articles for article (PubMed ID: 17916906)

  • 1. GRB-7 facilitates HER-2/Neu-mediated signal transduction and tumor formation.
    Bai T; Luoh SW
    Carcinogenesis; 2008 Mar; 29(3):473-9. PubMed ID: 17916906
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HER-2/neu transcriptionally activates Jab1 expression via the AKT/beta-catenin pathway in breast cancer cells.
    Hsu MC; Chang HC; Hung WC
    Endocr Relat Cancer; 2007 Sep; 14(3):655-67. PubMed ID: 17914096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tyrosine phosphorylation of PP2A is regulated by HER-2 signalling and correlates with breast cancer progression.
    Wong LL; Chang CF; Koay ES; Zhang D
    Int J Oncol; 2009 May; 34(5):1291-301. PubMed ID: 19360341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tyrosine kinase inhibitor emodin suppresses growth of HER-2/neu-overexpressing breast cancer cells in athymic mice and sensitizes these cells to the inhibitory effect of paclitaxel.
    Zhang L; Lau YK; Xia W; Hortobagyi GN; Hung MC
    Clin Cancer Res; 1999 Feb; 5(2):343-53. PubMed ID: 10037184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p185c-erbB-2 signal enhances cisplatin-induced cytotoxicity in human breast carcinoma cells: association between an oncogenic receptor tyrosine kinase and drug-induced DNA repair.
    Arteaga CL; Winnier AR; Poirier MC; Lopez-Larraza DM; Shawver LK; Hurd SD; Stewart SJ
    Cancer Res; 1994 Jul; 54(14):3758-65. PubMed ID: 7913407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p38MAPK-activated AKT in HER-2 overexpressing human breast cancer cells acts as an EGF-independent survival signal.
    Diehl KM; Grewal N; Ethier SP; Woods-Ignatoski KM
    J Surg Res; 2007 Sep; 142(1):162-9. PubMed ID: 17612563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HER-2/neu signal transduction in human breast and ovarian cancer.
    Reese DM; Slamon DJ
    Stem Cells; 1997; 15(1):1-8. PubMed ID: 9007217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells.
    Zhou BP; Liao Y; Xia W; Spohn B; Lee MH; Hung MC
    Nat Cell Biol; 2001 Mar; 3(3):245-52. PubMed ID: 11231573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The tumor suppression activity of E1A in HER-2/neu-overexpressing breast cancer.
    Chang JY; Xia W; Shao R; Sorgi F; Hortobagyi GN; Huang L; Hung MC
    Oncogene; 1997 Feb; 14(5):561-8. PubMed ID: 9053854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Green tea polyphenol epigallocatechin-3 gallate inhibits Her-2/neu signaling, proliferation, and transformed phenotype of breast cancer cells.
    Pianetti S; Guo S; Kavanagh KT; Sonenshein GE
    Cancer Res; 2002 Feb; 62(3):652-5. PubMed ID: 11830514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p130Cas as a new regulator of mammary epithelial cell proliferation, survival, and HER2-neu oncogene-dependent breast tumorigenesis.
    Cabodi S; Tinnirello A; Di Stefano P; BisarĂ² B; Ambrosino E; Castellano I; Sapino A; Arisio R; Cavallo F; Forni G; Glukhova M; Silengo L; Altruda F; Turco E; Tarone G; Defilippi P
    Cancer Res; 2006 May; 66(9):4672-80. PubMed ID: 16651418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blocking HER-2/HER-3 function with a dominant negative form of HER-3 in cells stimulated by heregulin and in breast cancer cells with HER-2 gene amplification.
    Ram TG; Schelling ME; Hosick HL
    Cell Growth Differ; 2000 Mar; 11(3):173-83. PubMed ID: 10768865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [SUCI02 inhibits HER-2/neu receptor tyrosine kinase phosphorylation and growth of HER-2/neu-overexpressing breast cancer cells].
    Zhu XF; Liu ZC; Xie BF; Cai LL; Yang DJ
    Ai Zheng; 2003 Aug; 22(8):790-4. PubMed ID: 12917021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of potential Stat3-regulated genes in human breast cancer.
    Hsieh FC; Cheng G; Lin J
    Biochem Biophys Res Commun; 2005 Sep; 335(2):292-9. PubMed ID: 16081048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HER-2/neu raises SHP-2, stops IFN-gamma anti-proliferation in bladder cancer.
    Su WP; Tu IH; Hu SW; Yeh HH; Shieh DB; Chen TY; Su WC
    Biochem Biophys Res Commun; 2007 Apr; 356(1):181-6. PubMed ID: 17346677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer.
    Massarweh S; Osborne CK; Jiang S; Wakeling AE; Rimawi M; Mohsin SK; Hilsenbeck S; Schiff R
    Cancer Res; 2006 Aug; 66(16):8266-73. PubMed ID: 16912207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kalopanaxsaponin A inhibits PMA-induced invasion by reducing matrix metalloproteinase-9 via PI3K/Akt- and PKCdelta-mediated signaling in MCF-7 human breast cancer cells.
    Park SK; Hwang YS; Park KK; Park HJ; Seo JY; Chung WY
    Carcinogenesis; 2009 Jul; 30(7):1225-33. PubMed ID: 19420016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological inhibition of fatty acid synthase (FAS): a novel therapeutic approach for breast cancer chemoprevention through its ability to suppress Her-2/neu (erbB-2) oncogene-induced malignant transformation.
    Menendez JA; Mehmi I; Verma VA; Teng PK; Lupu R
    Mol Carcinog; 2004 Nov; 41(3):164-78. PubMed ID: 15390078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Basic science of HER-2/neu: a review.
    Hung MC; Lau YK
    Semin Oncol; 1999 Aug; 26(4 Suppl 12):51-9. PubMed ID: 10482194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of the SNT-1/FRS2 phosphotyrosine binding domain inhibits activation of MAP kinase and PI3-kinase pathways and antiestrogen resistant growth induced by FGF-1 in human breast carcinoma cells.
    Manuvakhova M; Thottassery JV; Hays S; Qu Z; Rentz SS; Westbrook L; Kern FG
    Oncogene; 2006 Sep; 25(44):6003-14. PubMed ID: 16682955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.